Mar 12, 2024
BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...
Read More...
Nov 05, 2019
Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China. The shares purchased are worth USD 2.7 bill...
Read More...
Sep 04, 2019
The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. Opdivo, leading drug of Bristol-Myers Squibb approv...
Read More...
Aug 15, 2019
EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...
Read More...
Aug 17, 2018
Bexion Pharmaceuticals’ Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas Bexion Pharmaceuticals’ investigational cancer treatment, BXQ-350, is receiving lots of mainstream media coverage as a potential game-changer. BXQ-350 is a formulation of a syntheticall...
Read More...
Mar 09, 2017
Sanofi pays €120M to buy into AstraZeneca RSV program Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper